Skip to main content
Figure 1 | Radiation Oncology

Figure 1

From: mRNA-based vaccines synergize with radiation therapy to eradicate established tumors

Figure 1

Efficacy of RNA immunotherapy is strongly dependent on the tumor burden and time available for the induction of immune response. (A) C57BL/6 mice (n = 5 per group) were vaccinated 2 times (1 vaccination/week) either with OVA mRNA vaccine (32 μg) or buffer. After 7 days splenocytes from vaccinated mice were analyzed for IFN-γ secretion in response to Ovalbumin- or Connexin-derived epitope using an ELISpot assay. * - p = 0.0154 (B) C57BL/6 mice (n = 8 per group) were vaccinated 2 times (1 vaccination/week) either with OVA mRNA vaccine (64 μg), control vaccine (64 μg) or buffer. 6 days after the second vaccination, mice were challenged subcutaneously with 1 × 106 syngenic E.G7-OVA tumor cells. Tumor growth was monitored by measuring the tumor size in 3 dimensions using calipers. *** - p < 0.0001 (C) Expression of Ovalbumin in tumors escaping the control of the immune system, following prophylactic vaccination, was analyzed. Total RNA was isolated and OVA expression was quantified via qRT-PCR in relation to mGAPDH. ** - p = 0.0034 (D) C57BL/6 mice (n = 8 per group) were challenged s.c. with 0.3 × 106 syngenic E.G7-OVA tumor cells on day 0. On day 3 mice were treated either with OVA vaccine (32 μg), control vaccine (32 μg) or buffer. Tumor growth was monitored by measuring the tumor size in 3 dimensions using calipers. ** - p = 0.0091, ***- p < 0.001, ****- p < 0.0001. All presented data show representative results of at least two independent experiments.

Back to article page